Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birth

References

• BabischkinJSGrimesRWPepeGJAlbrechtEDEstrogen stimulation of P450 cholesterol side-chain cleavage activity in cultures of human placental syncytiotrophoblastsBiol Reprod19975612722789002660
   PubMed Web of Science ®Google Scholar
• VidaeffACRaminSMPotential biochemical events associated with initiation of laborCurr Med Chem200815661461918336276
   PubMed Web of Science ®Google Scholar
• MendelsonCRMinireview: fetal-maternal hormonal signaling in pregnancy and laborMol Endocrinol200923794795419282364
   PubMedGoogle Scholar
• VidaeffACRaminSMManagement strategies for the prevention of preterm birth. Part I: update on progesterone supplementationCurr Opin Obstet Gynecol200921648048419770761
   PubMed Web of Science ®Google Scholar
• IamsJDGoldenbergRLMercerBMThe preterm prediction study: can low-risk women destined for spontaneous preterm birth be identified?Am J Obstet Gynecol2001184465265511262467
   PubMed Web of Science ®Google Scholar
• HauthJCGilstrapLC3rdBrekkenALHauthJMThe effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military populationAm J Obstet Gynecol198314621871906682631
   PubMed Web of Science ®Google Scholar
• Carr-HillRAHallMHThe repetition of spontaneous preterm labourBr J Obstet Gynaecol19859299219284041398
   PubMedGoogle Scholar
• DoddJMFlenadyVCincottaRCrowtherCAPrenatal administration of progesterone for preventing preterm birthCochrane Database Syst Rev20061CD00494716437505
   PubMedGoogle Scholar
• LikisFEEdwardsDRAndrewsJCProgestogens for preterm birth prevention: a systematic review and meta-analysisObstet Gynecol2012120489790722955308
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationUpdated statement on compounded version of hydroxyprogesterone caproate Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm308546.htmAccessed June 16, 2013
   Google Scholar
• PetriniJRCallaghanWMKlebanoffMEstimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United StatesObstet Gynecol2005105226727215684150
   PubMed Web of Science ®Google Scholar
• MeisPJKlebanoffMThomEPrevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproateN Engl J Med2003384132379238512802023
   PubMed Web of Science ®Google Scholar
• ManuckTALaiYMeisPJProgesterone receptor polymorphisms and clinical response to 17 α-hydroxyprogesterone caproateAm J Obstet Gynecol20112052131. e1e5
   Web of Science ®Google Scholar
• SpongCYMeisPJThomEAProgesterone for prevention of recurrent preterm birth: impact of gestational age at previous deliveryAm J Obstet Gynecol20051933 Pt 21127113116157124
   PubMed Web of Science ®Google Scholar
• HowHYSibaiBMProgesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safetyTher Clin Risk Manag200951556419436604
   PubMedGoogle Scholar
• FonsecaEBCelikEParraMSinghMNicolaidesKHProgesterone and the risk of preterm birth among women with a short cervixN Engl J Med2007357546246917671254
   PubMed Web of Science ®Google Scholar
• GrobmanWAThomEASpongCY17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mmAm J Obstet Gynecol20122075390. e1e823010094
   PubMed Web of Science ®Google Scholar
• BerghellaVFigueroaDSzychowskiJM17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical lengthAm J Obstet Gynecol20102024351. e1e620350641
   PubMed Web of Science ®Google Scholar
• HassanSSRomeroRVidyadhariDVaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trialUltrasound Obstet Gynecol2011381183121472815
   PubMed Web of Science ®Google Scholar
• RomeroRNicolaidesKConde-AgudeloAVaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and meta-analysis of individual patient dataAm J Obstet Gynecol20122062124. e1e1922284156
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationAdvisory committees Available from: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm279859.htmAccessed March 5, 2012
   Google Scholar
• ByrnsMCRegulation of progesterone signaling during pregnancy: implications for the use of progestins for the prevention of preterm birthJ Steroid Biochem Mol Biol2112013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• RuddockNKShiSQJainGProgesterone, but not 17 α-hydroxyprogesterone caproate, inhibits human myometrial contractionsAm J Obstet Gynecol20081994391. e1e718928984
   PubMed Web of Science ®Google Scholar
• YanRFokinaVHankinsGDAhmedMSNanovskayaTNThe effect of esterases on 17 α-hydroxyprogesterone caproateAm J Obstet Gynecol20081982221. e1e5
   Web of Science ®Google Scholar
• TulchinskyDSimmerHSources of plasma 17 α-hydroxyprogesterone in human pregnancyJ Clin Endocrinol Metab19723567998084634481
   PubMed Web of Science ®Google Scholar
• SharmaSEllisECDorkoKMetabolism of 17 α-hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytesDrug Metab Dispos201038572372720097724
   PubMed Web of Science ®Google Scholar
• CuppettCDZhaoYCaritisSZhangSZhaoWVenkataramananREffect of endogenous steroid hormones on 17 α-hydroxyprogesterone caproate metabolismAm J Obstet Gynecol2013208186. e1e623063018
   PubMed Web of Science ®Google Scholar
• AttardiBJZeleznikASimhanHComparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17 α-hydroxyprogesterone caproate, and related progestinsAm J Obstet Gynecol20071976591. e1e9
   Web of Science ®Google Scholar
• MaherMAAbdelazizAEllaithyMBazeedMFPrevention of preterm birth: a randomized trial of vaginal compared with intramuscular progesteroneActa Obstet Gynecol Scand201392221522223016508
   PubMed Web of Science ®Google Scholar
• DoddJMFlenadyVJCincottaRCrowtherCAProgesterone for the prevention of preterm birth: a systematic reviewObstet Gynecol2008112112713418591318
   PubMed Web of Science ®Google Scholar
• CaritisSNRouseDJPeacemanAMPrevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate; a randomized controlled trialObstet Gynecol20091132 Pt 128529219155896
   PubMed Web of Science ®Google Scholar
• CombsCAGariteTMaurelKDasAPortoM17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trialAm J Obstet Gynecol20112043221. e1e821376161
   PubMed Web of Science ®Google Scholar
• LeiKChenLCryarBJUterine stretch and progesterone actionJ Clin Endocrionol Metab2011966E1013E1024
   Web of Science ®Google Scholar
• DurnwaldCPMomirovaVRouseDJSecond trimester cervical length and risk of preterm birth in women with twin gestation treated with 17-α hydroxyprogesterone caproateJ Matern Fetal Neonatal Med201023121360136420441408
   PubMed Web of Science ®Google Scholar
• SenatMVPorcherRWinerNPrevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trialAm J Obstet Gynecol20132083194. e1e823433324
   PubMed Web of Science ®Google Scholar
• CaritisSNSimhanHNZhaoYRelationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestationAm J Obstet Gynecol20122075396. e1e822959763
   PubMed Web of Science ®Google Scholar
• RouseDJCaritisSNPeacemanAMA trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twinsN Engl J Med2007357545446117671253
   PubMed Web of Science ®Google Scholar
• CombsCAGariteTMaurelKDasAPortoMFailure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trialAm J Obstet Gynecol20102033248. e1e920816146
   PubMed Web of Science ®Google Scholar
• VidaeffACDoes weekly progesterone prolong gestation in women who have PPROM?OBG Management20112351819
   Google Scholar
• BrieryCMVeillonEWKlauserCKWomen with preterm premature rupture of the membranes do not benefit from weekly progesteroneAm J Obstet Gynecol2011204154. e1e420869038
   PubMed Web of Science ®Google Scholar
• FacchinettiFPaganelliSComitiniGCervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproateAm J Obstet Gynecol20071965453. e1e417466698
   PubMed Web of Science ®Google Scholar
• RozenbergPChauveaudADeruellePPrevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trialAm J Obstet Gynecol20122063206. e1e922381603
   PubMed Web of Science ®Google Scholar
• DurnwaldCPLynchCDWalkerHIamsJDThe effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over timeAm J Obstet Gynecol20092014410. e1e519716117
   PubMed Web of Science ®Google Scholar
• YeminiMBorensteinRDreazenEPrevention of premature labor by 17 alpha-hydroxyprogesterone caproateAm J Obstet Gynecol198515155745773976757
   PubMed Web of Science ®Google Scholar
• RebarberACleary-GoldmanJIstwanNBThe use of 17 alpha-hydroxyprogesterone caproate (17P) in women with cervical cerclageAm J Perinatol200825527127518401840
   PubMed Web of Science ®Google Scholar
• Society for Maternal-Fetal Medicine Publications CommitteeProgesterone and preterm birth prevention: translating clinical trials data into clinical practiceAm J Obstet Gynecol2012206537638622542113
   PubMed Web of Science ®Google Scholar
• KeelerSMKieferDRochonMQuinonesJNNovetskyAPRustOA randomized trial of cerclage vs 17 α-hydroxyprogesterone caproate for treatment of short cervixJ Perinat Med200937547347919492920
   PubMed Web of Science ®Google Scholar
• HemauerSJYanRPatrikeenaSLTransplacental transfer and metabolism of 17-alpha-hydroxyprogesterone caproateAm J Obstet Gynecol20081992169. e1e518674659
   PubMed Web of Science ®Google Scholar
• CaritisSNSharmaSVenkataramananRPharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestationAm J Obstet Gynecol20122075398. e1e822967833
   PubMed Web of Science ®Google Scholar
• CaritisSNSharmaSVenkataramananRPharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestationAm J Obstet Gynecol2011205140. e1e821620357
   PubMed Web of Science ®Google Scholar
• SharmaSEllisECGramignoliRHepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytesDrug Metab Dispos201341229630423129211
   PubMed Web of Science ®Google Scholar
• VallejoMBrizOSerranoMAMonteMJMarinJJPotential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancyJ Hepatol20064461150115716458994
   PubMed Web of Science ®Google Scholar
• MagninGdeMeeus JBSarfatiRChaouchiOPaillatA[Elevated liver enzymes in a tocolytic treatment with micronized natural progesterone]. Cytolyse hépatique lors d’un traitement tocolytique par la progestérone naturelle microniséePresse Méd1996253102105 French8746082
   PubMed Web of Science ®Google Scholar
• BacqYSapeyTBréchotMCPierreFFignonADuboisFIntrahepatic cholestasis of pregnancy: a French prospective studyHepatology19972623583649252146
   PubMed Web of Science ®Google Scholar
• BenifleJLDumontMLevardonM[Effects of natural micronized progesterone on the liver in the third trimester of pregnancy]. Effets de la progest érone naturelle micronisée sur le foie au troisième trimestre de la grossesseContracept Fertil Sex1997252165169 French9116778
   PubMedGoogle Scholar
• ShermanAIHormonal therapy for control of the incompetent os of pregnancyObstet Gynecol19662831982055944836
   PubMed Web of Science ®Google Scholar
• OnsrudMPausEHaugEKjørstadKIntramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal functionActa Obstet Gynecol Scand19856465195232932883
   PubMed Web of Science ®Google Scholar
• CarbonneBRosenblattJPrevention of recurrent preterm birth: a comeback of progesterone?J Gynecol Obstet Biol Reprod200534Suppl 1S127S136
   Google Scholar
• RebarberAIstwanNBRusso-StieglitzKIncreased incidence of gestational diabetes in women receiving prophylactic 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm deliveryDiabetes Care20073092277228017563346
   PubMed Web of Science ®Google Scholar
• WatersTPSchultzBAMercerBMCatalanoPMEffect of 17α-hydroxyprogesterone caproate on glucose intolerance in pregnancyObstet Gynecol20091141454919546757
   PubMed Web of Science ®Google Scholar
• WolfeKDearmondCHowHHendersonZTSibaiBThe rates of abnormal glucose challenge tests and gestational diabetes in women receiving 17 α-hydroxyprogesterone caproateAm J Perinatol2011281074174621660898
   PubMed Web of Science ®Google Scholar
• DemirkiranMAslanKBicakciSBozdemirHOzerenATransient parkinsonism: induced by progesterone or pregnancy?Mov Disord200419111382138415389979
   PubMed Web of Science ®Google Scholar
• BandinoJPThoppilJKennedyJSHivnorCMIatrogenic autoimmune progesterone hepatitis caused by 17alpha-hydroxyprogesterone caproate for preterm labor preventionCutis201188524124322272488
   PubMed Web of Science ®Google Scholar
• CarmichaelSLShawGMLaurentCCroughanMSOlneyRSLammerEJMaternal progestin intake and risk of hypospadiasArch Pediatr Adolesc Med20051591095796216203941
   PubMedGoogle Scholar
• SeegmillerRENelsonGWJohnsonCKEvaluation of the teratogenic potential of delalutin (17alpha-hydroxyprogesterone caproate) in miceTeratology19832822012086648824
   PubMedGoogle Scholar
• ResseguieLJHickJFBruenJANollerKLO’FallonWMKurlandLTCongenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936–1974Fertil Steril19854345145193987922
   PubMed Web of Science ®Google Scholar
• PushpalathaTReddyPRReddyPSGestational exposure to hydroxyprogesterone caproate suppresses reproductive potential in male ratsNaturwissenschaften200592838538816049688
   PubMed Web of Science ®Google Scholar
• SchardeinJLBirchRHesleyRThorsrudBAMultigeneration reproductive study of hydroxyprogesterone caproate (HPC) in the rat: laboratory results and clinical significanceBirth Defects Res B Dev Reprod Toxicol201295216017422528880
   PubMedGoogle Scholar
• DudasJGidaiJCzeizelAEPopulation-based case-control teratogenic study of hydroprogesterone treatment during pregnancyCongenit Anom2006464194198
   Google Scholar
• NorthenATNormanGSAndersonKFollow-up of children exposed in utero to 17α-hydroxyprogesterone caproateObstet Gynecol2007110486587217906021
   PubMed Web of Science ®Google Scholar
• ChristianMSBrentRLCaldaPEmbryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the nonclinical literature for embryo-fetal toxicity with progestinsJ Matern Fetal Neonatal Med20072028911217437208
   PubMed Web of Science ®Google Scholar
• O’BrienJMLewisDFProgestins for the prevention of spontaneous preterm birth: review and implications of recent studiesJ Reprod Med2009542738719301570
   PubMed Web of Science ®Google Scholar
• HendrickxAGKorteRLeuschnerFEmbryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerateTeratology19873511291363563931
   PubMedGoogle Scholar
• HowHYBartonJIstwanNRheaDJStanzianoGJProphylaxis with 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?Am J Obstet Gynecol20071973260. e1e417826411
   PubMed Web of Science ®Google Scholar
• RebarberAFerraraLAHanleyMLIncreased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproateAm J Obstet Gynecol20071963224. e1e417346529
   PubMed Web of Science ®Google Scholar
• D’ArcanguesCOnce-a-month estrogen/progestogen injectablesEntre Nous Cph Den1991191512222332
   PubMedGoogle Scholar
• ReijndersFJThomasCMDoesburgWHRollandREskesTKEndocrine effects of 17alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trialBr J Obstet Gynaecol19899554624683135831
   PubMedGoogle Scholar
• KlebanoffMAMeisPJDombrowskiMPSalivary progesterone and estriol among pregnant women treated with 17-α-hydroxyprogesterone caproate or placeboAm J Obstet Gynecol20081995506. e1e718456237
   PubMed Web of Science ®Google Scholar
• CritchleyHOJonesRLLeaRGRole of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancyJ Clin Endocrinol Metab19998412402489920091
   PubMed Web of Science ®Google Scholar
• TibbettsTAConneelyOMO’MalleyBWProgesterone via its receptor antagonizes the pro-inflammatory activity of estrogen in the mouse uterusBiol Reprod19996051158116510208978
   PubMed Web of Science ®Google Scholar
• ElovitzMWangZMedroxyprogesterone acetate, but not progesterone, protects against inflammation-induced parturition and intrauterine demiseAm J Obstet Gynecol2004190369370115042001
   PubMed Web of Science ®Google Scholar
• VidaeffACRaminSMGilstrapLC3rdBishopKDAlcornJLImpact of progesterone on cytokine-stimulated nuclear factor-kappaB signaling in HeLa cellsJ Matern Fetal Neonatal Med2007201232817437195
   PubMed Web of Science ®Google Scholar
• NoldCMaubertMAntonLYellonSElovitzMAPrevention of preterm birth by progestational agents: what are the molecular mechanisms?Am J Obstet Gynecol20132083223. e1e723433326
   PubMed Web of Science ®Google Scholar